Toxoplasma gondii infection in patients with malignant and benign bone tumours

Cover Page


Cite item

Full Text

Abstract

Toxoplasma gondii (T. gondii) is an intracellular parasite that infects humans, and seroprevalence of its infection varies from about 10 to 80 percent in different countries with a higher prevalence in warmer and humid regions. In this study, the rate of acute and chronic toxoplasmosis in patients with benign or malignant bone tumours was investigated. Fifty-three patients who suffered from various bone tumours, as well as sixty-five healthy controls with an unknown sero-logical profile for anti-Toxoplasma antibodies, were enrolled in this cross-sectional study. Anti-Toxoplasma antibodies were detected in serum samples using enzyme-linked immunosorbent assay (ELISA) and blood samples of them were used for real-time PCR. Thirty-two (60.32%) and twenty-one (39.63%) of patients had malignant tumours and benign tumours, respectively. The results showed a higher and significant seropositivity rate of IgM antibodies in primary bone tumour patients compared to the control group and Toxoplasma DNA became positive in 18.86% of patients with primary bone tumours and 6.15% of controls. Surprisingly, the high presence of parasite DNA was detected in patients with malignant tumours. The seroprevalence of T. gondii IgM antibodies and DNA positivity among the cancer patients were significantly higher than healthy individuals. Also, chronic toxoplasmosis (it was shown with IgG positive) appears to be more common in people with benign cancers than malignancies. The study showed a relatively high seroprevalence of anti-T. gondii antibodies in patients with primary bone cancer. However, the considerable rate of positive blood samples for the presence of parasite’s DNA should not be ignored. A key to the effective management of diseases in immunosuppressed individuals is prompt and accurate diagnosis of toxoplasmosis. Moreover, it seems that PCR tests may be more reliable than serological methods and it could be considered as a precise method for diagnosis of acute toxoplasmosis.

About the authors

M. Hajizadeh

Iran University of Medical Sciences

Email: maryamhajizadeh@gmail.com

PhD Student (Medical Parasitology), Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences.

Tehran.

Иран

R. Falak

Iran University of Medical Sciences

Email: falak.r@iums.ac.ir

Associate Professor, Department of Medical Immunology, School of Medicine, Iran University of Medical Sciences.

Tehran.

Иран

M. Tavakoli-Yaraki

Iran University of Medical Sciences

Email: masoumeh.tavakoli@gmail.com

MSc, PhD, Associate Professor, Department of Biochemistry, School of Medicine, Iran University of Medical Sciences.

Tehran.

Иран

R. Hosseinzadeh

Iran University of Medical Sciences

Email: Hosseinzadeh@gmail.com

MSc (Medical Parasitology), Department of Medical Immunology, School of Medicine, Iran University of Medical Sciences

Tehran.

Иран

M. Alipour

Iran University of Medical Sciences

Email: alipour.mry@gmail.com

Student, Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences.

Tehran.

Иран

E. Ahmadpour

Tabriz University of Medical Sciences

Email: ahmadpour@gmail.com

Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences.

Tabriz.

Иран

R. Rafiei-Sefiddashti

Iran University of Medical Sciences

Author for correspondence.
Email: rafiei.r@iums.ac.ir

Raheleh Rafiei-Sefiddashti - Associate Professor, Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences.

Tehran.

Phone: +0098 912 340-43-82, +0098 218 670-32-63

Иран

References

  1. Ahmadpour E., Daryani A., Sharif M., Sarvi S., Aarabi M., Mizani A., Rahimi M.T., Shokri A. Toxoplasmosis in immuno-compromised patients in Iran: a systematic review and meta-analysis. J. Infect. Dev. Ctries, 2014, vol. 8, no. 12, pp. 1503–1510. doi: 10.3855/jidc.4796
  2. Ahmadpour E., Pishkarie-Asl R., Spotin A., Samadi Kafil H., Didarlu H., Azadi Y., Barac A. Sero-molecular evaluation of Toxoplasma gondii infection among HIV-positive patients. Trans. R. Soc. Trop. Med. Hyg., 2019, vol. 113, no. 12, pp. 771–775. doi: 10.1093/trstmh/trz082
  3. Ahmadpour E., Zargami E., Mahami-Oskouei M., Spotin A., Shahbazi A., Kafil H.S., Rajabi S., Alizadeh P., Azadi Y., Bahaj R., Shahrivar F., Barac A. Diagnosis of Toxoplasma gondii infection in pregnant women using automated chemiluminescence and quantitative real time PCR. Asian Pacific Asian Pac. J. Trop. Med., 2019, vol. 12, no. 1, pp. 26–31.
  4. Anvari D., Sharif M., Sarvi S., Aghayan S.A., Gholami S., Pagheh A.S., Hosseini S.A., Saberi R., Chegeni T.N., Hosseininejad Z., Daryani A. Seroprevalence of Toxoplasma gondii infection in cancer patients: a systematic review and meta-analysis. Microb. Pathog., 2019, vol. 129, pp. 30–42. doi: 10.1016/j.micpath.2019.01.040
  5. Arab-Mazar Z., Fallahi S., Koochaki A., Haghighi A., Tabaei S.J.S. Immunodiagnosis and molecular validation of Toxoplasma gondii-recombinant dense granular (GRA) 7 protein for the detection of toxoplasmosis in patients with cancer. Microbiol. Res., 2016, vol. 183, pp. 53–59. doi: 10.1016/j.micres.2015.11.006
  6. Carmen J.C., Sinai A.P. Suicide prevention: disruption of apoptotic pathways by protozoan parasites. Mol. Microbiol., 2007, vol. 64, no. 4, pp. 904–916. doi: 10.1111/j.1365-2958.2007.05714.x
  7. Cong W., Liu G.H., Meng Q.F., Dong W., Qin S.Y., Zhang F.K., Zhang X.Y., Wang X.Y., Qian A.D., Zhu X.Q. Toxoplasma gondii infection in cancer patients: prevalence, risk factors, genotypes and association with clinical diagnosis. Cancer Lett., 2015, vol. 359, no. 2, pp. 307–313. doi: 10.1016/j.canlet.2015.01.036
  8. Daryani A., Sarvi S., Aarabi M., Mizani A., Ahmadpour E., Shokri A., Shokri A., Rahimi M.T., Sharif M. Seroprevalence of Toxoplasma gondii in the Iranian general population: a systematic review and meta-analysis. Acta Tropica, 2014, vol. 137, pp. 185–194. doi: 10.1016/j.actatropica.2014.05.01
  9. De la Luz Galvan-Ramirez M., Troyo R., Roman S., Calvillo-Sanchez C., Bernal-Redondo R. A systematic review and meta-analysis of Toxoplasma gondii infection among the Mexican population. Parasites Vectors, 2012, vol. 5, no. 1: 271. doi: 10.1186/1756-3305-5-271
  10. Dorfman H.D., Czerniak B. Bone cancers. Cancer, 1995, vol. 75, no. 1, pp. 203–210. doi: 10.1002/1097-0142(19950101)75:1+<203::aid-cncr2820751308>3.0.co;2-
  11. Dubey J., Jones J. Toxoplasma gondii infection in humans and animals in the United States. Int. J. Parasitol., 2008, vol. 38, no. 11, pp. 1257–1278. doi: 10.1016/j.ijpara.2008.03.007
  12. Dupont C.D., Christian D.A., Hunter C.A. Immune response and immunopathology during toxoplasmosis. Semin. Immunopathol., 2012, vol. 34, no. 6, pp. 793–813. doi: 10.1007/s00281-012-0339-3
  13. Embil J., Covert A., Howes W., Tanner C., Staudt M. Visualization of Toxoplasma gondii in the cerebrospinal fluid of a child with a malignant astrocytoma. Can. Med. Assoc. J., 1985, vol. 133, no. 3, pp. 213–214.
  14. Ewald P.W. An evolutionary perspective on parasitism as a cause of cancer. Adv. Parasitol., 2009, vol. 68, pp. 21–43. doi: 10.1016/S0065-308X(08)00602-7
  15. Fitzpatrick R. The strange case of the transfer of training estimate. Ind. Organ. Psychol., 2001, vol. 39, no. 2, pp. 18–19.
  16. Gleason T.H., Hamlin W.B. Disseminated toxoplasmosis in the compromised host: a report of five cases. Arch. Intern. Med., 1974, vol. 134, no. 6, pp. 1059–1062.
  17. Hassanzadeh M., Rasti S., Hooshyar H., Momen-Heravi M., Soliemani A., Mousavi S.G.A. Seroepidemiology of Toxoplasma gondii infection in immunodeficiency patients in Kashan and Qom during 2014–2015. FEYZ, 2017, vol. 21, no. 5, pp. 483–489.
  18. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. Cancer J. Clin., 2011, vol. 61, no. 2, pp. 69–90. doi: 10.3322/caac.20107
  19. Khabaz M.N., Elkhateeb L., Al-Alami J. Reactivation of latent Toxoplasma gondii in immunocompromised cancer patients. Comp. Clin. Pathol., 2011, vol. 20, no. 2, pp. 183–186. doi: 10.1007/s00580-010-0975-8
  20. Klastersky J., Aoun M. Opportunistic infections in patients with cancer Ann. Oncol., 2004, vol. 15, no. 4, pp. iv329–iv335. doi: 10.1093/annonc/mdh947
  21. Kusne S., Dummer J.S., Ho M., Whiteside T., Rabin B.S., Makowka L., Esquivel C.O., Starzl T.E. Self-limited Toxoplasma parasitemia after liver transplantation. Transplantation, 1987, vol. 44, no. 3, pp. 457–458.
  22. Liu Q., Wang Z.-D., Huang S.-Y., Zhu X.-Q. Diagnosis of toxoplasmosis and typing of Toxoplasma gondii. Parasites Vectors, 2015, vol. 8, no. 1: 292. doi: 10.1186/s13071-015-0902-6
  23. Mechain B., Garin Y.J.F., Robert-Gangneux F., Dupouy-Camet J., Derouin F. Lack of utility of specific immunoglobulin G antibody avidity for serodiagnosis of reactivated toxoplasmosis in immunocompromised patients. Clin. Diagn. Lab. Immunol., 2000, vol. 7, no. 4, pp. 703–705. doi: 10.1128/CDLI.7.4.703-705.2000
  24. Pradhan S., Yadav R., Mishra V.N. Toxoplasma meningoencephalitis in HIV-seronegative patients: clinical patterns, imaging features and treatment outcome. Trans. R. Soc. Trop. Med. Hyg., 2007, vol. 101, no. 1, pp. 25–33. doi: 10.1016/j.trst-mh.2006.02.021
  25. Roozbehani M., Falak R., Mohammadi M., Hemphill A., Razmjou E., Meamar A.R., Masoori L., Khoshmirsafa M., Moradi M., Gharavi M.J. Characterization of a multi-epitope peptide with selective MHC-binding capabilities encapsulated in PLGA nanoparticles as a novel vaccine candidate against Toxoplasma gondii infection. Vaccine, 2018, vol. 36, no. 41, pp. 6124–1632. doi: 10.1016/j.vaccine.2018.08.068
  26. Rouatbi M., Amairia S., Amdouni Y., Boussaadoun M.A., Ayadi O., Al-Hosary A.A.T., Rekik M., Ben Abdallah R., Aoun K., Darghouth M.A., Wieland B., Gharbi M. Toxoplasma gondii infection and toxoplasmosis in North Africa: a review. Parasite, 2019, vol. 26. doi: 10.1051/parasite/2019006
  27. Safarpour H., Cevik M., Zarean M., Barac A., Hatam-Nahavandi K., Rahimi M.T., Bannazadeh Baghi H., Koshki T.J., Pagheh A.S., Shahrivar F., Ebrahimi M., Ahmadpour E. Global status of Toxoplasma gondii infection and associated risk factors in people living with HIV. AIDS, 2020, vol. 34, no. 3, pp. 469–474. doi: 10.1097/QAD.0000000000002424
  28. Sasai M., Pradipta A., Yamamoto M. Host immune responses to Toxoplasma gondii. Int. Immunol., 2018, vol. 30, no. 3, pp. 113–139. doi: 10.1093/intimm/dxy004
  29. Sharif M., Daryani A., Ebrahimnejad Z., Gholami S., Ahmadpour E., Borhani S., Lamsechi N. Seroprevalence of anti-Toxoplasma IgG and IgM among individuals who were referred to medical laboratories in Mazandaran province, northern Iran. J. Infect. Public Health, 2016, vol. 9, no. 1, pp. 75–80. doi: 10.1016/j.jiph.2015.06.006
  30. Verma N., Tyagi A., Singh P., Tyagi M., Rathi M., Sharma S. Incidence of bone tumors and tumor like lesions at a tertiary centre — a study of 64 cases. J. Res. Med. Sci., 2018, vol. 6, no. 2, pp. 533. doi: 10.18203/2320-6012.ijrms20180293
  31. Wang Z.-D., Liu H.-H., Ma Z.-X., Ma H.-Y., Li Z.-Y., Yang Z.-B., Zhu X.Q., Xu B., Wei F., Liu Q. Toxoplasma gondii infection in immunocompromised patients: a systematic review and meta-analysis. Front. Microbiol., 2017, vol. 8: 389. doi: 10.3389/fmicb.2017.00389
  32. Yuan Z., Gao S., Liu Q., Xia X., Liu X., Liu B., Hu R. Toxoplasma gondii antibodies in cancer patients. Cancer Lett., 2007, vol. 254, no. 1, pp. 71–74. doi: 10.1016/j.canlet.2007.02.011

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Hajizadeh M., Falak R., Tavakoli-Yaraki M., Hosseinzadeh R., Alipour M., Ahmadpour E., Rafiei-Sefiddashti R.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies